cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

Company profile
Ticker
AVTX
Exchange
Website
CEO
Michael F. Cola
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cerecor Inc.
SEC CIK
Corporate docs
Subsidiaries
Medgenics Medical (Israel) Ltd. • Aevi Genomic Medicine Europe ...
AVTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
13 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Sep 23
8-K
Avalo Enters into Agreement to Divest AVTX-800 Series
12 Sep 23
8-K
Other Events
11 Sep 23
8-K
Entry into a Material Definitive Agreement
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Aug 23
8-K
Entry into a Material Definitive Agreement
7 Aug 23
424B5
Prospectus supplement for primary offering
7 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
3 Aug 23
Latest ownership filings
4
Magnus Persson
5 Jul 23
4
June Sherie Almenoff
5 Jul 23
SC 13G/A
Caissa Capital Management ltd.
29 Jun 23
4
Steven Boyd
28 Jun 23
SC 13D/A
ARMISTICE CAPITAL, LLC
28 Jun 23
4
Change in insider ownership
27 Jun 23
4
Change in insider ownership
20 Jun 23
4
Change in insider ownership
14 Jun 23
4
Christopher Ryan Sullivan
13 Jun 23
4
GARRY ARTHUR NEIL
13 Jun 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.45 mm | 6.45 mm | 6.45 mm | 6.45 mm | 6.45 mm | 6.45 mm |
Cash burn (monthly) | 3.48 mm | 419.75 k | 2.73 mm | 1.91 mm | 3.68 mm | 1.61 mm |
Cash used (since last report) | 9.79 mm | 1.18 mm | 7.68 mm | 5.37 mm | 10.35 mm | 4.53 mm |
Cash remaining | -3.33 mm | 5.27 mm | -1.23 mm | 1.08 mm | -3.89 mm | 1.93 mm |
Runway (months of cash) | -1.0 | 12.6 | -0.5 | 0.6 | -1.1 | 1.2 |
Institutional ownership, Q2 2023
21.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 5 |
Closed positions | 11 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 847.65 mm |
Total shares | 4.37 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 1.35 mm | $4.68 mm |
VR Adviser | 1.25 mm | $444.00 mm |
Armistice Capital | 588.85 k | $294.00 k |
Nantahala Capital Management | 556.20 k | $197.56 mm |
Vanguard | 222.07 k | $78.88 mm |
BLK Blackrock | 124.45 k | $44.20 mm |
Geode Capital Management | 80.97 k | $28.76 mm |
Millennium Management | 33.93 k | $12.05 mm |
Virtu Financial | 32.59 k | $12.00 k |
STT State Street | 25.64 k | $9.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jun 23 | Armistice Capital | Common Stock | Sell | Dispose S | Yes | No | 0.5194 | 937,404 | 486.89 k | 731,458 |
26 Jun 23 | Caissa Capital Management | Common Stock | Buy | Dispose P | No | No | 0.62 | 182,300 | 113.03 k | 0 |
26 Jun 23 | Caissa Capital Management | Common Stock | Buy | Dispose P | Yes | No | 0.6433 | 1,425,700 | 917.15 k | 0 |
26 Jun 23 | Armistice Capital | Common Stock | Sell | Dispose S | Yes | No | 0.6125 | 2,746,138 | 1.68 mm | 1,668,862 |
20 Jun 23 | Caissa Capital Management | Common Stock | Buy | Acquire P | Yes | No | 4.1444 | 2,000 | 8.29 k | 1,425,700 |
16 Jun 23 | Caissa Capital Management | Common Stock | Buy | Acquire P | Yes | No | 3.9048 | 3,000 | 11.71 k | 1,423,700 |
15 Jun 23 | Caissa Capital Management | Common Stock | Buy | Acquire P | Yes | No | 3.6837 | 3,160 | 11.64 k | 1,420,700 |
14 Jun 23 | Caissa Capital Management | Common Stock | Buy | Acquire P | Yes | No | 3.479 | 6,000 | 20.87 k | 1,417,540 |
13 Jun 23 | Caissa Capital Management | Common Stock | Buy | Acquire P | Yes | No | 3.8216 | 8,750 | 33.44 k | 1,411,540 |
12 Jun 23 | Caissa Capital Management | Common Stock | Buy | Acquire P | Yes | No | 4.3352 | 2,149 | 9.32 k | 1,402,790 |
News
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
22 Sep 23
12 Health Care Stocks Moving In Friday's Intraday Session
22 Sep 23
What's Going On With Avalo Therapeutics (AVTX) Stock?
22 Sep 23
Nasdaq Rises 50 Points; US Manufacturing PMI Improves In September
22 Sep 23
12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Sep 23
Press releases
Avalo Enters into Agreement to Divest AVTX-800 Series
12 Sep 23
Thinking about buying stock in Electriq Power Holdings, Growth for Good Acquisition, Nio Inc, Neptune Wellness Solutions, or Avalo Therapeutics?
21 Aug 23
Avalo to Participate in SVB Securities Therapeutics Forum
6 Jul 23
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
26 Jun 23